Analytical Data
-
Gene name
BARK
- Application
-
Alternative Names
ADRbK1; B-ARK1; bARK1; Beta-ARK1; GRK2; G-protein coupled receptor kinase 2; Adrenergic Receptor Beta Kinase 1
-
Species
Human
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P25098
-
Expression Region
Asp398~Leu640
-
Molecular Weight
58kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BARK (B-Alpha Receptor Kinase) is a member of a group of protein kinases that play a critical role in regulating G protein-coupled receptor (GPCR) signaling, a fundamental pathway implicated in numerous physiological processes and diseases. With the discovery that BARK selectively phosphorylates activated GPCRs, researchers have become increasingly interested in its potential as a therapeutic target for conditions such as heart disease, neurodegenerative disorders, and cancer. The understanding of BARK's structure and function was significantly enhanced through the development of recombinant protein technology, allowing for the expression and purification of BARK in sufficient quantities for detailed biochemical studies. Researchers have utilized various techniques, including site-directed mutagenesis and crystallography, to elucidate the molecular mechanisms underlying BARK's role in modulating GPCR activity. This research is crucial for uncovering the intricacies of cell signaling pathways and developing innovative drug strategies aimed at influencing BARK activity to restore normal function in disease states. As a result, BARK has emerged as a promising candidate in the field of pharmacology and drug design, making its study not only academically intriguing but also of significant clinical relevance.
